Several ERBB3-directed monoclonal antibodies, bispecific antibodies, and emerging antibody–drug conjugates demonstrated encouraging clinical outcomes that enhance therapeutic efficacy and address resistance, particularly when combined with other anti-cancer strategies [40]. Here, ERBB3 is linked to cancer.